PD-L1 inhibition in gastroesophageal junction cancer

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the promising post hoc analyses from randomized clinical trials and Phase II non-randomized trials investigating anti-PD-L1 treatments for gastroesophageal junction (GEJ) tumors. Such studies show impressive overall response rates and a low rate of early disease progression in patients with microsatellite instable (MSI) gastroesophageal junction tumors. In this population, there are the highest ever-recorded long-term outcomes reported to date, and single-agent immunotherapy may also be an option. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_filippo_pietrantonio
• #institution_fondazione_irccs_istituto_nazionale_dei_tumori
• #event_esmo_gi_2024
• #format_interview
• #subject_gastroesophageal_cancer
• #subject_gastrointestinal_cancer
• #field_immuno_oncology
• #field_treatment
• #field_trial_updates
• #medicines_checkpoint_inhibitors
• #medicines_antibodies
• #pd_l1
• #microsatellite_instable
• #msi
• #gej